What Rofixdol Treats: Main Uses and Benefits

Rofixdol, containing Ketoprofen, is generally used in situations involving certain distressing symptoms and is applied across domains where additional symptomatic support is needed. The medicine provides supportive relief across multiple symptom axes.

The medication is commonly used across conditions characterized by periods of heightened symptoms that include pain, inflammation, and fever. Clinically, it is considered relevant for easing acute pain following minor trauma like sprains or strains and for managing chronic symptoms associated with osteoarthritis and rheumatoid arthritis. It is also applied in contexts involving episodic distress, such as menstrual cramps, as well as local inflammatory states like a sore throat or pain following dental procedures.

“It is considered relevant for managing symptom clusters that may become intense or disruptive, especially when they interfere with daily comfort.”

This supportive relief helps to ease the overall symptom burden, contributing to easing discomfort and assisting patients with maintaining functional stability during episodes of heightened discomfort.

---

Focus on Symptom Relief: Joint Stiffness
In chronic inflammatory conditions, Rofixdol helps address the associated stiffness and swelling, which supports the patient during difficult episodes and may support greater ease of movement.

Regulatory References

1. Ketoprofen: MedlinePlus Drug Information

The eligibility for Rofixdol (Ketoprofen) is strictly defined by government regulatory documents, focusing on populations who must not use the medicine (contraindications) and those who require conditional use.

Contraindicated Populations

Rofixdol is strictly prohibited for individuals with a known allergy to Ketoprofen or other NSAIDs, including a history of aspirin-sensitive asthma. Use is also contraindicated in the presence of severe organ failure, specifically severe hepatic, renal, or heart failure, as well as an active peptic ulcer or a history of gastrointestinal bleeding/perforation. The medicine must not be used for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Physiological Restrictions

Use is contraindicated during the third trimester of pregnancy and is generally not recommended during lactation. For the pediatric population, safety and effectiveness are typically not established, resulting in a prohibition or non-recommendation for children under specific age limits (e.g., 14 or 18 years).

Conditional Use

Older adults and patients with mild or moderate renal or hepatic impairment are categorized as requiring conditional use. Eligibility in these groups is associated with necessary dosage adjustment and close monitoring due to an increased risk of serious adverse events. Rofixdol is generally established for use in adults.

Rofixdol (Ketoprofen) is subject to several clinically significant interactions documented in regulatory labeling. The co-administration of Rofixdol with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including high-dose aspirin and COX-2 selective inhibitors, is officially restricted due to a compounded risk of serious gastrointestinal adverse events. Use for the management of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery is formally contraindicated.

Interaction Type	Interacting Products	Interaction Outcome
Pharmacodynamic Risk	Oral Anticoagulants, SSRIs, Corticosteroids	Documented risk of increased bleeding and GI ulceration.
Exposure Alteration	Lithium, Methotrexate	Reduced renal clearance of these products, leading to elevated and prolonged plasma concentrations.

Furthermore, the efficacy of Diuretics and ACE Inhibitors/ARBs may be reduced, and this combination carries an officially documented risk of renal impairment. Alcohol consumption is restricted due to its compounding effect on the risk of serious gastrointestinal bleeding. In patients with renal impairment, there is a noted risk of the drug's metabolite accumulating and converting back to the active compound, potentially increasing systemic exposure. The overall interaction structure is defined by these critical risk reinforcement and clearance modification patterns, as classified by regulatory authorities.

Modulating Eicosanoid Synthesis via COX Inhibition

Rofixdol (Ketoprofen) acts by the non-selective, reversible competitive inhibition of both Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This molecular action blocks the Arachidonic Acid Cascade , suppressing the formation of prostaglandins ( PGE2), which are key chemical mediators. This inhibition leads to the physiological consequences of decreased vascular permeability and reduced tissue edema. This domain defines the biochemical basis of the drug's effect profile.

---

Dampening Nociception and Central Thermoregulation

The suppression of PGE2 has two principal system-level consequences. At the periphery, it prevents the chemical sensitization of nociceptors, thereby limiting the transmission of amplified nociceptive signals. Centrally, the inhibition of PGE2 within the hypothalamus allows the body's thermal set point to reset. This action limits the heightened responsiveness of sensory nerves and modulates nociceptive signal transmission. This central mechanism triggers heat-dissipating mechanisms, such as peripheral vasodilation, which modulates PGE2-mediated thermoregulation. The use of Ketoprofen lysine salt in certain formulations accelerates the rate of COX inhibition by linking dissolution kinetics to rapid target access.

Rofixdol, containing Ketoprofen, is administered through both systemic oral and localized cutaneous routes, reflecting the available forms. Systemic forms include immediate-release (IR) and extended-release (ER) capsules, as well as granules in a sachet (Ketoprofen lysine salt). The oral immediate-release formulations are typically dosed multiple times per day, often every six to eight hours, with individual doses ranging from 25 mg to 75 mg. The total daily intake for immediate-release forms is generally limited to a maximum of 300 mg. Conversely, the extended-release capsules are administered as a 200 mg dose once daily and are not indicated for acute use.

Administration of oral forms may be done with food, milk, or an antacid to minimize potential gastrointestinal discomfort. Granules contained in the sachet formulation are explicitly instructed to be placed onto the tongue and swallowed, which may be done with or without water.

Usage patterns over time are differentiated by formulation. The immediate-release forms are intended for short-term use, while the extended-release form is utilized for the management of chronic conditions, where the lowest effective dose should be maintained for the shortest duration necessary. Specific adjustments to the administration schedule are mandated for certain patient groups. Older adults and individuals with documented renal or hepatic impairment require a reduction in the initial dosage. For example, the maximum dose for severe renal impairment is limited to 100 mg/day. The topical gel is applied locally two to four times a day with gentle massage, and the instructions specify that it should not be covered with occlusive dressings.

Research evidence / Overview of studies for Rofixdol

Evidence for Use in Acute Pain and Symptom Management

The research base for Rofixdol, containing Ketoprofen, comes from short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews applied in research contexts involving fluctuating or unstable symptoms. These studies primarily focused on adult populations in populations experiencing acute episodes, such as pain following surgery or minor trauma.

Research examined outcomes related to physical discomfort. Researchers typically monitored measures like the intensity of pain and the time required for the measured change to begin. Findings describe patterns observed in the studies related to the rate of change and the overall change measured during these short periods. For the study of fever, research explored short-term symptom changes, specifically focusing on children (infants six months and older). The research contributes to the evidence landscape; however, long-term patterns of fever control are not characterized.

Research in Chronic Inflammatory Conditions

Ketoprofen, the active ingredient, was evaluated in studies examining patient-reported experiences for conditions characterized by fluctuating or episodic manifestations, specifically osteoarthritis and rheumatoid arthritis. Research reports changes measured during the study period for outcomes related to physical discomfort and outcomes describing episodic changes. The evidence contributes to understanding symptom patterns and is relevant only to the study of symptoms, as the studies did not explore any modification of the underlying chronic disease process.

Long-Term Study Duration and Follow-up

An important characteristic of the research landscape is that follow-up durations were limited across many studies. The core effectiveness evidence, especially for acute pain, is based on short-term research. Data for long-term outcomes for continuous use of the oral form remain limited. The durability of measured response and sustained patterns of symptom control over many months or years are not fully characterized by the existing effectiveness trials.

Key Evidence Gaps and Areas of Uncertainty

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Several limitations are noted across the research base. Evidence quality varies across studies, and some trials have modest sample sizes. The findings reflect the specific study results and cannot predict whether an individual will respond similarly to the group averages.

Key Studies & References

1. Ketoprofen: Overview of Uses and Supportive Relief - MedlinePlus Drug Information
2. Clinical Trials Database Query (Used to determine study types and populations)

Common questions about Rofixdol (FAQ)

---

Q: How quickly does Rofixdol typically start working?

Official prescribing information indicates that the immediate-release forms of Rofixdol are generally absorbed quickly. Peak levels of the medicine in the blood typically occur between 30 minutes and 2 hours after taking a dose when fasting. Taking the medicine with food may cause the rate of absorption to be slowed down.

---

Q: How long does the effect of one dose of Rofixdol usually last?

The elimination half-life, which describes how long it takes for half of the medicine to be cleared from the body, is approximately 2 to 2.5 hours for the immediate-release form. This duration is generally aligned with the typical suggested dosing intervals for symptomatic relief, which are often every six to eight hours.

---

Q: Is Rofixdol safe to take if I have liver problems?

Official regulatory documents strictly prohibit the use of Rofixdol for individuals with severe hepatic (liver) failure. For patients with mild or moderate liver impairment, the medicine may be used, but close medical monitoring and a reduced initial dosage are required. Regulatory information indicates that a healthcare provider should assess pre-existing liver conditions when considering use.

---

Q: How does Rofixdol affect the central nervous system?

Regulatory documents mention several neurological effects related to the central nervous system (CNS). These reported side effects include dizziness, general sleepiness (somnolence), headache, and difficulty sleeping (insomnia). These effects are reported to potentially influence mental alertness.

---

Q: What is the difference between Rofixdol tablets and capsules?

Rofixdol is available in both immediate-release and extended-release capsule forms, along with other formats. The immediate-release type is designed for rapid absorption into the body. Conversely, the extended-release capsules are specifically formulated to release the active ingredient at a slower, controlled rate over a longer period, making them appropriate for different types of conditions.

---

Q: What is the maximum duration Rofixdol is typically prescribed for?

The immediate-release formulations are officially intended for short-term management of acute conditions. For chronic condition management using the extended-release form, regulatory guidance states that use should be limited to the lowest effective dose for the shortest possible duration necessary to manage symptoms.

---

Q: What if I take a vitamin or herbal supplement while using Rofixdol?

Official labeling identifies several drug classes that interact with Rofixdol, particularly those that increase the risk of bleeding. The interaction profile does not typically list specific vitamins, but some herbal supplements may influence blood coagulation. The potential for adverse events related to blood coagulation necessitates careful consideration when combining the medicine with any supplement that may influence this process.

---

Q: Does taking Rofixdol interfere with the effect of birth control pills?

Official documentation does not widely cite an interaction between Rofixdol and oral contraceptives (birth control pills). However, the potential for drug interactions affecting the metabolism of hormones is a general consideration in pharmacology that has not been fully characterized in all official documents.

---

Q: Can Rofixdol be used by children?

Official product information states that the safety and effectiveness of the systemic oral forms of Rofixdol have not been established in the pediatric population. Due to this, the medicine is generally not recommended or is prohibited for children below a specific age limit, which is typically 16 or 18 years old, depending on the product’s regulatory approval.

---

Q: Are there any age limits for who can take Rofixdol?

Yes, official documents note age restrictions for systemic oral use. The medicine is typically not recommended for use in children under a specified age (often 16 or 18 years) because safety and effectiveness in that group are not established. Older adults are also noted as a population that requires specific dosage adjustment and close monitoring due to increased risk of serious adverse events.

---

Q: What is the most frequently reported side effect of Rofixdol?

The most common adverse events associated with the systemic use of Rofixdol are typically related to the gastrointestinal system. These frequently reported issues include symptoms such as nausea, indigestion (dyspepsia), and various forms of abdominal discomfort.

---

Q: Do most people experience side effects when taking Rofixdol?

Official regulatory documents do not state a claim that 'most people' experience side effects, as the information is based on incidence rates observed in clinical studies. Adverse events are documented in regulatory sources to reflect the potential effects observed across groups of patients in clinical research.

---

Q: Is it normal to feel a little dizzy after starting Rofixdol?

Yes, dizziness is listed in official prescribing information as a reported side effect associated with the systemic use of Rofixdol. As dizziness is reported, the official information indicates a potential for impaired mental alertness.

---

Q: What kind of stomach issues are mentioned in official documents for Rofixdol?

Regulatory documents describe a range of gastrointestinal issues linked to the medicine. These include common discomforts like nausea and indigestion, as well as more serious potential events such as bleeding, ulceration, and perforation of the stomach or intestines.

---

Q: Is Rofixdol a controlled substance?

No, Rofixdol (Ketoprofen) is not classified as a controlled substance under the U.S. Controlled Substances Act or similar regulations. It is not listed as having a known risk of misuse or physical dependence.

---

Q: Does Rofixdol affect alertness or the ability to drive?

Rofixdol is associated with neurological side effects such as sleepiness (somnolence) and dizziness. Because of this potential, official warnings advise that caution should be exercised before engaging in activities that require full attention, such as driving, until you know how the medicine may affect you.

---

Q: Can Rofixdol cause sleeplessness or insomnia?

Yes, difficulty sleeping, or insomnia, is specifically documented in the official prescribing information as a reported neurological adverse effect associated with the systemic use of the medicine.

---

Q: Can Rofixdol cause a change in appetite or weight?

Official documents containing post-marketing adverse event reports list changes in appetite, including loss of appetite, as potential effects of the active ingredient. Additionally, changes in body weight (either gain or loss) have also been reported.

---

Q: Does Rofixdol require any special monitoring by a doctor?

Yes, close medical monitoring is specifically required for certain patient groups. Individuals who are older adults or who have pre-existing mild to moderate kidney or liver impairment require regular checking of their organ function due to an increased risk of serious adverse events.

---

Q: Are headaches a common side effect of Rofixdol?

Headache is documented in official prescribing information among the reported neurological side effects associated with the systemic use of Rofixdol.

---

Q: Do official sources mention Rofixdol being addictive?

No, official sources confirm that Rofixdol (Ketoprofen) is not classified as a controlled substance and does not have a documented risk of misuse, addiction, or physical dependence.

---

Q: What does the research say about Rofixdol's effectiveness?

Clinical trial summaries indicate that the active ingredient has demonstrated efficacy when compared to a placebo. The research supports its use in managing the symptoms of acute pain and inflammation, as well as symptoms associated with chronic conditions like arthritis.

---

Q: Is Rofixdol available in different strengths or forms?

Yes, Rofixdol is officially available in several different dosage forms. These include immediate-release and extended-release capsules, and granules for systemic (oral) use, as well as topical forms such as mouthwash or oral spray for localized use.

---

Q: Is there a generic version of Rofixdol available?

Yes, the active ingredient in Rofixdol, Ketoprofen, is widely available in generic formulations that are approved by government drug authorities.

---

Q: Can I use Rofixdol if I have a known allergy to similar drugs?

No, the medicine is strictly contraindicated (prohibited) for individuals with a known allergy or hypersensitivity to the active substance, any inactive ingredients in the product, or to other medicines classified as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as aspirin.

The official regulatory instructions specify strict conditions for the storage and disposal of Rofixdol.

Storage Requirements

Rofixdol must be stored at controlled room temperature, defined as 68 F to 77 F (20 C to 25 C), with excursions permitted up to 86 F (30 C). The medicine must be protected from moisture and must be kept in its original container, which should remain tightly closed.

For safety, Rofixdol must be stored out of the sight and reach of children.

Disposal Procedures

Unused or expired Rofixdol should be disposed of in accordance with local regulations. The preferred method is to utilize an official drug take-back program. If a take-back program is not available, the medicine must be prepared for disposal in household trash by mixing it with an undesirable substance, such as dirt or used coffee grounds, and sealing the mixture in a bag before discarding.